Entrada Therapeutics (TRDA) Net Equity Issued and Repurchased (2021 - 2024)

Entrada Therapeutics' Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at -$392000.0 for Q3 2024.

• In Q3 2024, Net Equity Issued and Repurchased changed N/A year-over-year to -$392000.0; the TTM figure through Dec 2025 stood at -$392000.0 (down 100.39% YoY), while the FY2024 annual figure was $99.6 million, up 413.26% from the prior year.
• Net Equity Issued and Repurchased for Q3 2024 stood at -$392000.0, down from $100.0 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $116.2 million in Q1 2021, with the low at -$417000.0 in Q2 2021.
• The 3-year median for Net Equity Issued and Repurchased is $19.4 million (2023), against an average of $47.0 million.